Drug Trial Radar · NCT06621563
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
780
Planned (sponsor's estimate)
Start
Dec 14, 2024
Primary completion
Mar 30, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.
Conditions
- Solid Tumors
- Non-Small Cell Lung Cancer
- Colorectal Cancer
Interventions
HS-20117 combined HS-20093Drug
HS-20117 + HS-20093
HS-20117 combined Platinum-containing chemotherapyDrug
HS-20117 + cisplatin/carboplatin + pemetrexed
HS-20117 combined HS-20093 and 5-FUDrug
HS-20117 + HS-20093 + 5-FU
HS-20117+CAPEOXDrug
CAPOEX: Oxaliplatin+Capecitabine
HS-20117+FOLFIRIDrug
FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU
HS-20117+mFOLFOX6Drug
mFOLFOX6=Oxaliplatin+Leucovorin Calcium+5-FU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse eventsTime frame: rom the date of first dose to 90 days after the final dose.
- Tolerability of HS-20117 combination therapy: incidence of DLT events, maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-20117 in combination therapies.Time frame: From the date of first dose to day 21.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.